Simon Waters

2.8k total citations
31 papers, 941 citations indexed

About

Simon Waters is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Simon Waters has authored 31 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Simon Waters's work include Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (9 papers). Simon Waters is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (9 papers). Simon Waters collaborates with scholars based in United Kingdom, United States and France. Simon Waters's co-authors include Norman B. Hecht, R Distel, Rüdiger Schmitt, Josef Altenbuchner, Peter Rogowsky, J. Grinsted, Chris Twelves, Sacha J. Howell, Patricia A. Bower and Angela Casbard and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Simon Waters

30 papers receiving 910 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Waters United Kingdom	15	407	322	286	237	145	31	941
Julie A. Vendrell France	21	905 2.2×	563 1.7×	308 1.1×	259 1.1×	538 3.7×	55	1.5k
Maria Rosaria De Filippo Italy	19	532 1.3×	289 0.9×	167 0.6×	239 1.0×	455 3.1×	32	1.3k
Kristine L. Skele United States	7	658 1.6×	283 0.9×	288 1.0×	125 0.5×	242 1.7×	8	1.2k
Kevin M. Regan United States	16	1.1k 2.6×	240 0.7×	341 1.2×	220 0.9×	230 1.6×	19	1.3k
Chih‐Jian Lih United States	14	628 1.5×	181 0.6×	122 0.4×	110 0.5×	114 0.8×	22	1.3k
Liya Ding United States	15	831 2.0×	468 1.5×	171 0.6×	90 0.4×	342 2.4×	21	1.3k
Takehisa Matsumoto Japan	22	1.4k 3.4×	288 0.9×	84 0.3×	162 0.7×	285 2.0×	44	1.8k
James L. Prescott United States	14	359 0.9×	109 0.3×	295 1.0×	153 0.6×	66 0.5×	19	748
Nancy Uhrhammer France	23	903 2.2×	566 1.8×	146 0.5×	588 2.5×	536 3.7×	62	1.6k
Laura Lawrie United Kingdom	14	772 1.9×	161 0.5×	107 0.4×	63 0.3×	180 1.2×	14	1.1k

Countries citing papers authored by Simon Waters

Since Specialization

Citations

This map shows the geographic impact of Simon Waters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Waters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Waters more than expected).

Fields of papers citing papers by Simon Waters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Waters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Waters. The network helps show where Simon Waters may publish in the future.

Co-authorship network of co-authors of Simon Waters

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Waters. A scholar is included among the top collaborators of Simon Waters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Waters. Simon Waters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fasching, Peter A., Daniil Stroyakovskiy, Denise A. Yardley, et al.. (2024). LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Annals of Oncology. 35. S1207–S1207. 17 indexed citations

Loi, Samantha M., Erica Stringer-Reasor, Jean‐Sébastien Frenel, et al.. (2024). 235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE. Annals of Oncology. 35. S310–S311. 1 indexed citations

Symeonides, Stefan N., Duncan Wheatley, Stephen Chan, et al.. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment. 199(1). 35–46. 8 indexed citations

Kaklamani, Virginia, François‐Clément Bidard, Patrick Neven, et al.. (2023). Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).. Journal of Clinical Oncology. 41(16_suppl). 1070–1070. 4 indexed citations

Bardia, Aditya, Gabriel N. Hortobágyi, Oleg Lipatov, et al.. (2023). LBA23 Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC). Annals of Oncology. 34. S1261–S1262.

Mehta–Shah, Neha, Pier Luigi Zinzani, Jasmine Zain, et al.. (2023). Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology. Hematological Oncology. 41(S2). 499–500. 6 indexed citations

Okines, Alicia, Jeremy Braybrooke, Iain R. Macpherson, et al.. (2023). Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).. Journal of Clinical Oncology. 41(16_suppl). TPS1111–TPS1111. 2 indexed citations

Howell, Sacha J., Angela Casbard, Margherita Carucci, et al.. (2022). Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology. 23(7). 851–864. 87 indexed citations

Wildiers, Hans, Sandrine Marréaud, Lissandra Dal Lago, et al.. (2022). Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. The Breast. 64. 100–111. 14 indexed citations

10.

Saura, Cristina, Judit Matito, Mafalda Oliveira, et al.. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 27(21). 5818–5827. 15 indexed citations

11.

Piccart, Martine, Manuel Ruíz Borrego, H-T. Arkenau, et al.. (2021). 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Annals of Oncology. 32. S478–S479. 4 indexed citations

12.

Jones, Robert H., Angela Casbard, Margherita Carucci, et al.. (2020). Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology. 21(3). 345–357. 159 indexed citations

13.

Cameron, David, Murray Brunt, Peter Schmid, et al.. (2020). Abstract P3-11-09: ARISTACAT - Aromatase inhibition plus minus saracatinib as advanced breast cancer therapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer. Cancer Research. 80(4_Supplement). P3–11. 1 indexed citations

14.

Battisti, Nicolò Matteo Luca, Belinda Kingston, James P. King, et al.. (2019). Abstract P6-18-23: Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience. Cancer Research. 79(4_Supplement). P6–18. 1 indexed citations

15.

Battisti, Nicolò Matteo Luca, Belinda Kingston, Judy King, et al.. (2019). Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment. 174(3). 731–740. 15 indexed citations

16.

Wildiers, Hans, Konstantinos Tryfonidis, Lissandra Dal Lago, et al.. (2018). Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. The Lancet Oncology. 19(3). 323–336. 81 indexed citations

17.

Tanaka, Tomoyuki, et al.. (2010). Single Domain Intracellular Antibodies from Diverse Libraries. Journal of Biological Chemistry. 286(5). 3707–3716. 33 indexed citations

18.

Waters, Simon, Kamal U. Saikh, & Janet Stavnezer. (1989). A B-Cell-Specific Nuclear Protein That Binds to DNA Sites 5′ to Immunoglobulin Sα Tandem Repeats Is Regulated during Differentiation. Molecular and Cellular Biology. 9(12). 5594–5601. 14 indexed citations

19.

Hecht, Norman B., Patricia A. Bower, Simon Waters, Pamela C. Yelick, & R Distel. (1986). Evidence for haploid expression of mouse testicular genes. Experimental Cell Research. 164(1). 183–190. 87 indexed citations

20.

Waters, Simon, R Distel, & Norman B. Hecht. (1985). Mouse testes contain two size classes of actin mRNA that are differentially expressed during spermatogenesis.. Molecular and Cellular Biology. 5(7). 1649–1654. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact